Department of Health and Social Care
Government invests in global partnership to treat gonorrhoea
The £3.5 million investment will help develop new treatments for gonorrhoea and make them available to low- and middle-income countries.
The investment is part of a continued partnership with the Global Antibiotic Research and Development Partnership (GARDP), a not-for-profit research and development organisation co-founded by the World Health Organization and the Drugs for Neglected Disease initiative in 2016.
- enable global access to treatment, including in low- and middle-income countries where the burden of antimicrobial resistance (AMR) is greatest
- fund GARDP’s development of oral antibiotic zoliflodacin, which is now in the last stage of clinical trials before reaching the market
Zoliflodacin is one of the few antibiotics in development to specifically treat gonorrhoea and is significant as treatments for gonorrhoea are becoming less effective.
There have been cases of gonorrhoea developing resistance to recommended treatments, including in the UK.
Gonorrhoea is among the most common sexually-transmitted infections (STIs), with an estimated 87 million new cases globally every year.
The STI can have severe consequences on public health and, when left untreated, serious consequences for reproductive health as well as increased risk of transmission of HIV and other STIs.
Women, and marginalised and vulnerable groups are disproportionately affected.
Gonorrhoea has been identified as posing a significant threat to global health by the World Health Organization (WHO). There is now an urgent need for new treatment options, particularly for people in developing countries.
Addressing drug-resistant infections is critical to achieving the UN’s sustainable development goals, particularly the target for good health and wellbeing for all.
GARDP will now start pharmaceutical development activities for zoliflodacin, and will develop a new strategy for access and appropriate use in low- and middle-income countries that have a high number of cases of gonorrhoea.
Minister for Innovation, Nicola Blackwood, yesterday said:
The UK is a global leader in tackling antimicrobial resistance, a threat that is posing serious risks to health and the global economy, as well as killing hundreds of thousands of people around the world each year.
It is vital to fund new antibiotic research and development to tackle AMR and this innovative project will develop solutions to treat the global rise of gonorrhoea and improve the quality of people’s lives.
Dr Manica Balasegaram, Executive Director of GARDP, yesterday said:
We are excited to unveil our new strategy, 5 BY 25, outlining GARDP’s ambition to accelerate the development of 5 new treatments by 2025.
The recent initiation of the phase 3 trial of zoliflodacin is an important milestone towards bringing one of our 5 treatments a step closer to patients by 2025.
The global nature of the trial, across 4 continents, represents our commitment to ensuring this treatment is available to anyone in need, wherever they live.
Latest News from
Department of Health and Social Care
HIV in the UK: towards zero HIV transmissions by 203017/01/2020 10:10:10
A new report by Public Health England shows that HIV transmission in the UK has continued to fall.
UK Government tackles heart disease with new partnership15/01/2020 13:10:00
The UK Government has announced its intent to pursue an innovative new collaboration to tackle heart disease with pharmaceutical company Novartis.
NHS funding bill enters Parliament15/01/2020 12:10:00
The NHS Long Term Plan Funding Bill will enshrine in law an extra £33.9 billion a year by 2024 for the NHS.
New heart disease drug to be made available for NHS patients14/01/2020 14:15:00
The government is collaborating with pharmaceutical company Novartis to launch a clinical trial for new cholesterol treatment.
Patients get same-day appointments with local pharmacists13/01/2020 15:10:00
People with minor illnesses or who need medicine urgently have been referred to local pharmacies, relieving pressure on doctors.
Wuhan novel coronavirus and avian flu: advice for travel to China13/01/2020 10:10:10
PHE is aware of a reported outbreak of a novel coronavirus in Wuhan City, China, and has offered advice to travellers to the area regarding this as well as the ongoing avian flu risk.
Carbapenamase producing enterobacterales: framework of actions08/01/2020 15:05:00
This framework provides information to providers of health and social care on how the spread of CPE can be minimised.
£40 million investment to reduce NHS staff login times06/01/2020 10:10:10
The new investment in frontline technology will free up thousands of NHS staff hours each day by improving how staff access computer systems.